Quality of Life in Patients With Rectal Cancer Receiving Total Mesorectal Excision With or Without Stoma
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Apr 3, 2018
Trial Information
Current as of May 02, 2025
Terminated
Keywords
ClinConnect Summary
In most cases it is recommended that patients after low anterior resection with TME and neoadjuvant chemoradiotherapy for rectal cancer need a temporarily diverting stoma. Recent evidence suggests that this is not always necessary. The decision for or against a stoma is made by the surgeon in charge and is based on an algorithm of risk factors for anastomotic leakage. Many patients receive an adjuvant chemotherapy postoperative. This may influence the quality of life e.a. due to mucositis and urge incontinency or the stoma itself.The objective of this pilot study is to establish the basis f...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age older than 18,
- • low anterior resection and TME due to rectum carcinoma after standardized neoadjuvant combined chemo- and radiotherapy and receiving adjuvant postoperative chemotherapy,
- • German speaking patient who is capable to fill in the questionnaire,
- • signed informed consent
- Exclusion Criteria:
- • age younger than 18,
- • preoperative stoma,
- • not German speaking
- • inability to fill in the questionnaire,
- • no standardized chemo- and radiotherapy
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Patients applied
Trial Officials
Susanne Drews, MD
Principal Investigator
Claraspital Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials